Dopamine agonist monotherapy in early Parkinson's disease

    Research output: Contribution to journalArticle

    1 Citation (Scopus)


    While levodopa therapy for Parkinson's disease is still considered the gold standard, motor complications are significant disadvantages of treatment. Monotherapy with dopamine agonists may present an alternative approach with a reduced likelihood of developing dyskinesias. Further studies are required before a definitive judgment can be made.
    Original languageEnglish
    Pages (from-to)8-11
    Number of pages4
    JournalHospital Medicine
    Publication statusPublished - 1 Jan 2003


    Dive into the research topics of 'Dopamine agonist monotherapy in early Parkinson's disease'. Together they form a unique fingerprint.

    Cite this